VA must stock new non-opioid pain drugs within a year

What it does

This bill requires the VA to add newly approved non-opioid pain medications to its national formulary within one year of FDA approval, and to include them on the drug standardization list. It defines non-opioid pain drugs as FDA-approved medications that reduce post-operative or post-surgical pain without acting on opioid receptors. Veterans gain access to newer pain-management alternatives; the VA must implement the change within 90 days.

Why we flagged it

The bill is a straightforward mandate to expand VA access to non-opioid pain medications. It is a public-health measure aimed at improving veteran care and reducing opioid dependence, with no narrow private carve-outs or hidden riders.

What the text implies

• The bill ties VA formulary inclusion to Medicare/Medicaid payment determinations (Social Security Act § 1833(t)(16)(G) and CFR § 416.174), meaning VA adoption follows federal payment policy rather than independent clinical review—this may accelerate adoption of expensive new drugs if Medicare deems them separately payable.
• The one-year timeline for inclusion may create pressure on VA pharmacy systems to rapidly integrate new drugs, potentially straining implementation capacity or clinical vetting processes.
• Exclusion of funding from the Cost of War Toxic Exposures Fund (§ 324) suggests the bill's costs come from general VA appropriations, not a dedicated opioid-crisis fund, which may compete with other veteran services for resources.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Veterans gain access to newly approved non-opioid pain medications, expanding treatment options for post-operative and post-surgical pain management. The mandate addresses the opioid crisis by ensuring VA formularies keep pace with FDA-approved alternatives, reducing reliance on opioids for pain management.

Who stands to gain

• pharmaceutical manufacturers of non-opioid pain medications
• biotech companies developing post-operative pain alternatives

Named in the bill

Department of Veterans Affairs, Secretary of Veterans Affairs, Food and Drug Administration, Centers for Medicare & Medicaid Services, Social Security Act § 1833(t)(16)(G), 42 CFR § 416.174, 38 USC § 8125, 38 USC § 324 (Cost of War Toxic Exposures Fund)

Where it stands

35 cosponsors: 25 Democrats, 10 Republicans.

• Jul 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 17, 2025 — Referred to House Committee on Veterans' Affairs · Congress.gov: “Referred to the House Committee on Veterans' Affairs”
• Jan 13, 2026 — Hearing held · Congress.gov: “Subcommittee Hearings Held”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,030,451 in lobbying spend. A filing names 56 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Greg Landsman, the sponsor, reported $1,006,728 in PAC receipts in the 2026 cycle.

• American Psychological Association Services Inc.(fka American Psychological Assn — $340,000 on 1 filing
• Disabled American Veterans — $310,451 on 2 filings
• Baker Hughes Company — $220,000 on 2 filings
• American Benefits Council Obo Alliance to Fight for Health Care — $160,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.